Abstract
PROCEPT BioRobotics will report its first‑quarter 2026 financial results Post Market on April 29, 2026; this preview outlines consensus expectations for revenue of 80.51 million US dollars, an adjusted EPS estimate of -0.56, and key themes around procedure growth, recurring consumables, and system placements ahead of management’s update.
Market Forecast
Based on current projections, PROCEPT BioRobotics is expected to deliver first‑quarter 2026 revenue of 80.51 million US dollars, up 22.57% year over year, with an adjusted EPS estimate of -0.56 and an EBIT estimate of -33.29 million US dollars; year over year, the EPS forecast implies a 13.56% decline and the EBIT forecast implies a 12.51% decline. Forecast margins for the quarter are not provided in the dataset, so we omit them here.
The main business continues to center on installed-base expansion and procedure utilization that supports recurring revenue from disposables, which in turn underpins gross-margin resilience and forms the core of the near-term growth thesis. The most promising segment remains handpieces and other consumables at 181.45 million US dollars in segment revenue, supported by the company’s focus on scaling procedure volumes; year‑over‑year segment growth was not specified.
Last Quarter Review
In the prior quarter, PROCEPT BioRobotics reported revenue of 76.38 million US dollars (up 11.94% year over year), a gross profit margin of 60.63%, a GAAP net loss attributable to shareholders of 29.85 million US dollars with a net profit margin of -39.07%, and an adjusted EPS of -0.53 (down 51.43% year over year).
A key financial highlight was the sequential change in net profit, which registered a quarter‑on‑quarter move of -39.39%, underscoring a larger net loss on a sequential basis despite solid top‑line growth. By business mix, handpieces and other consumables contributed 181.45 million US dollars, system sales and leases 106.13 million US dollars, and services 20.48 million US dollars; segment‑level year‑over‑year rates were not disclosed, but the company’s overall revenue still expanded 11.94% year over year.
Current Quarter Outlook
Main business: procedure growth and installed‑base monetization
The core engine for PROCEPT BioRobotics this quarter is expected to be procedure growth on the installed base, translating into recurring consumable revenue that drives a large share of gross profit. The revenue estimate of 80.51 million US dollars, up 22.57% year over year, implies a healthy increase in throughput relative to the prior year’s early‑year run rate, which is consistent with a larger base of active systems and improving utilization as hospital teams gain experience. With the prior quarter’s gross margin at 60.63%, the incremental revenue expected in the first quarter should remain margin‑accretive if the sales mix leans toward disposables; however, an uptick in capital system placements can temporarily weigh on the consolidated margin given accounting treatment and mix effects. Utilization cadence is the critical variable: higher case volumes naturally compound the recurring revenue stream, while installation and training timing can shift revenue recognition for capital systems between weeks or months within the quarter.
Management has emphasized organizational discipline and patient‑centric solutions in recent communications, setting the stage for a more balanced growth profile between capital and recurring revenue lines. Against that background, this quarter’s setup favors procedures and handpieces as volume expands from the growing installed base while the company continues to work on widening hospital adoption. The near‑term read‑through for profitability is complicated by the forecast EBIT of -33.29 million US dollars (a 12.51% year‑over‑year decline in the estimate), but strong top‑line growth can still create operating‑leverage opportunities later in the year if opex growth moderates and training‑related costs normalize. Investors will look for management commentary that clarifies how procedure momentum and installed‑base productivity are trending relative to internal targets and whether the company can maintain the gross‑margin profile observed in the last quarter.
Most promising business: consumables as the recurring growth flywheel
The consumables line remains the central recurring component of the company’s model, with segment revenue reported at 181.45 million US dollars in the reference dataset—by far the largest contribution among the company’s categories. Given the first‑quarter revenue forecast of 80.51 million US dollars, a material portion of quarterly gross profit should again be supported by disposables tied directly to procedure volumes. This dynamic is important because recurring revenue has the potential to offset volatility in capital sales and to keep gross margins resilient; the last reported gross margin of 60.63% provides a credible benchmark for what the business can generate when mix and utilization are favorable.
A constructive setup for the quarter hinges on three factors: case growth trajectories at established centers, the activation pace for newly installed systems, and any changes in pricing or contract terms that influence per‑procedure economics. As sites mature, per‑system procedure volume tends to increase, which positively influences consumables revenue and improves predictability. If the company reports signs of consistent utilization across cohorts—such as quarter‑over‑quarter case growth per active account—that would argue for sustained strength in consumables and greater visibility on cash conversion. Conversely, if utilization is uneven or training bottlenecks slow ramp‑up at new sites, consumables growth could underperform even with the installed base expanding, and management would need to articulate corrective actions to sustain the revenue trajectory suggested by the 22.57% year‑over‑year forecast. The balance of commentary on utilization versus placements will be a focal point for assessing how much of the 2026 growth curve is driven by recurring revenue versus capital sales.
Key stock‑price drivers this quarter: execution, guidance cadence, and cost discipline
This quarter’s share‑price reaction is likely to be most sensitive to three disclosures: the pace of procedures relative to expectations, any update to full‑year revenue and margin cadence, and signals on spending control after the prior quarter’s wider loss. On revenue, the 80.51 million US‑dollar estimate embeds a robust year‑over‑year gain; a beat driven by recurring items would likely be received more constructively than one driven by capital sales, because it would speak to demand durability and margin support. On profitability, investors will parse gross‑margin commentary for evidence that the mix continues to favor consumables and that scale effects are beginning to offset training, service, and field‑support costs. Given the EBIT estimate of -33.29 million US dollars and the EPS estimate of -0.56, the path to improving operating leverage—and any signposts on when quarterly losses begin to narrow—will be closely scrutinized.
Cost discipline and operating cadence are particularly relevant after the previous quarter’s shortfall versus expectations and the step‑up in losses. Any commentary on hiring pace, salesforce productivity, or prioritization of commercial investments could influence the market’s 2026 margin trajectory assumptions. Finally, qualitative disclosures on the hospital capital environment and the company’s order‑to‑installation timelines may help investors contextualize the split between capital and recurring revenue and smooth out near‑term volatility in quarterly comparisons. If management can pair a clean revenue print with evidence of stable gross margin and a credible plan to moderate operating expense growth, it would strengthen confidence in the company’s ability to convert procedure momentum into improving earnings quality across 2026.
Analyst Opinions
Across the period from January 1, 2026 to April 22, 2026, collected analyst commentary skews bullish over bearish on PROCEPT BioRobotics, with approximately 67% bullish and 33% bearish among the views considered. On the constructive side, TD Cowen’s Josh Jennings reaffirmed a Buy rating with a 50.00‑US‑dollar price target, highlighting confidence in the company’s multi‑year growth roadmap and framing 2026 expectations as achievable in light of procedure growth and commercial execution. Truist maintained a Buy rating while adjusting its target to 30.00 US dollars, signaling continued positive stance despite near‑term volatility and explicitly tying the outlook to sustained adoption, consumables growth, and a disciplined approach to cost structure. These bullish perspectives emphasize the durability of the recurring revenue model, the expanding installed base that seeds future consumable demand, and the potential for operating leverage as volume scales.
Parsing the core of the bullish thesis, analysts point to the company’s growing procedure footprint as the primary catalyst for 2026, which aligns with the first‑quarter revenue estimate rising 22.57% year over year to 80.51 million US dollars. Supportive views stress that recurring consumables enhance revenue visibility and can help maintain gross‑margin quality, evidenced by the last quarter’s 60.63% gross margin and a business model that increasingly monetizes utilization rather than relying solely on capital placements. In this framework, the negative year‑over‑year estimates for EBIT (-12.51%) and EPS (-13.56%) are seen less as structural deterioration and more as a function of front‑loaded investments and mix effects that can moderate as the year progresses. The bullish camp also argues that the sell‑side downward revisions and more cautious ratings earlier in the year reset expectations to a level where upside from consistent procedure execution can be recognized, particularly if management communicates clear milestones around utilization and operating expense discipline.
Looking into the quarter, optimistic analysts expect three confirmation points. First, procedure growth that translates into consumables revenue growth consistent with or better than the 22.57% year‑over‑year revenue forecast, demonstrating momentum beyond one‑off equipment orders. Second, indications that new sites are activating on schedule, with early evidence of developing utilization that supports the case‑mix and margin structure. Third, commentary that the company remains on track with a measured operating plan, setting the groundwork for loss narrowing later in 2026 despite the current quarter’s EBIT and EPS estimates. Should these elements materialize, bullish analysts believe the company can reestablish a cadence of outperformance versus consensus on the top line and, over time, narrow losses as operating leverage emerges from scale.
In summary, the majority view anticipates a constructive print on recurring revenue and an outlook that reiterates confidence in the company’s capacity to translate installed‑base growth into sustained top‑line expansion. The key to validating this stance will be management’s color on utilization consistency, gross‑margin guardrails, and a credible route to tighter operating spend—factors that, together, would underpin the expected 22.57% year‑over‑year revenue growth and support the Buy ratings from TD Cowen and Truist in the face of earlier, more cautious calls.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments